Antidiabetic Therapies Affect Risk of Pancreatic Cancer

Gastroenterology

Volumn 137, Issue 2, 2009, Pages 482-488

  Li, Donghui ^a   Yeung, Sai Ching J ^a   Hassan, Manal M ^a   Konopleva, Marina ^a   Abbruzzese, James L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN DERIVATIVE; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INSULIN; INSULIN DERIVATIVE; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ANAMNESIS; ARTICLE; CANCER RISK; CONTROLLED STUDY; DIABETES MELLITUS; DRUG USE; FEMALE; HUMAN; INTERVIEW; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; RISK FACTOR;

EID: 67650945180     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.04.013     Document Type: Article

References (32)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Anderson K., Mack T.M., and Silverman D.T. Cancer of the pancreas. In: Schottenfeld D., and Fraumeni Jr. J.F. (Eds). Cancer epidemiology and prevention. 3rd ed. (2006), Oxford University Press, New York, NY 721-762
3. Chari S.T., Leibson C.L., Rabe K.G., et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 134 (2008) 95-101
4. Pannala R., Leirness J.B., Bamlet W.R., et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 134 (2008) 981-987
5. Everhart J., and Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 273 (1995) 1605-1609
6. Huxley R.A., Ansary-Moghaddam A., de Gonzalez B., et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92 (2005) 2076-2083
7. Calle E.E., and Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4 (2004) 579-591
8. Giovannucci E., and Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 132 (2007) 2208-2225
9. Jones J., and Clemmons D. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16 (1995) 3-34
10. Ding X.-Z., Fehsenfeld D.M., Murphy L.O., et al. Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression. Pancreas 21 (2000) 310-320
11. Berstein L.M. Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer. Cancer Lett 224 (2005) 203-212
12. Evans J.M.M., Donnelly L.A., Emslie-Smith A.M., et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 330 (2005) 1304-1305
13. Bowker S.L., Majumdar S.R., Veugelers P., et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29 (2006) 254-258
14. Dilman V.M., Berstein L.M., Zabezhinski M.A., et al. Inhibition of DMBA-induced carcinogenesis by phenformin in the mammary glands of rats. Arch Geschwulstforsch 43 (1978) 1-8
15. Anisimov V.N., Semenchenko A.V., and Yashin A.I. Insulin and longevity: antidiabetic biguanides as geroprotectors. Biogerontology 4 (2003) 303-313
16. Bonnefont-Rousselot D., Raji B., Walrand S., et al. An intracellular modulation of free radical production could contribute to the beneficial effects of metformin towards oxidative stress. Metabolism 52 (2003) 586-589
17. Ben Sahra I., Laurent K., Loubat A., et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27 (2008) 3576-3586
18. Schneider M.B., Matsuzaki H., Haorah J., et al. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 120 (2001) 1263-1270
19. Hassan M.M., Wolff R.A., Bondy M.L., et al. Risk factors for pancreatic cancer: synergy of smoking with family history of pancreatic cancer and diabetes mellitus. Am J Gastroenterol 102 (2007) 2696-2707
20. Spitz M.R., Fueger J.J., and Newell G.R. The development of a comprehensive, institution-based patient risk evaluation program: II. Validity and reliability of questionnaire data. Am J Prev Med 4 (1988) 188-193
21. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 31 (2008) S12-S54
22. Kirpichnikov D., McFarlane S.I., and Sowers J.R. Metformin: an update. Ann Intern Med 137 (2002) 25-33
23. Hundal R.S., and Inzucchi S.E. Metformin: new understandings, new uses. Drugs 63 (2003) 1879-1894
24. Fryer L.G., Parbu-Patel A., and Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct pathways. J Biol Chem 277 (2002) 25226-25232
25. Hadad S.M., Fleming S., and Thompson A.M. Targeting AMPK: a new therapeutic opportunity in breast cancer. Crit Rev Oncol Hemat 67 (2008) 1-7
26. Williams T., and Brenman J.E. LKB1 and AMPK in cell polarity and division. Trends Cell Biol 18 (2008) 193-198
27. Zakikhani M., Dowling R., Fantus I.G., et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66 (2006) 10269-10273
28. Buzzai M., Jones R.G., Amaravadi R.K., et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67 (2007) 6745-6752
29. Anisimov V.N., Egormin P.A., Bershtein L.M., et al. Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice. Bull Exp Biol Med 139 (2005) 721-723
30. Cavanaugh K.L., Merkin S.S., Plantinga L.C., et al. Accuracy of patients' reports of comorbid disease and their association with mortality in ESRD. Am J Kidney Dis 52 (2008) 118-127
31. Wang F., Gupta S., and Holly E.A. Diabetes mellitus and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California. Cancer Epidemiol Biomarkers Prev 15 (2006) 1458-1463
32. Silverman D.T., Schiffman M., Everhart J., et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 80 (1999) 1830-1837